-
Inventiva has been picked for inclusion in Euronext’s new section alongside additional than 100 superior-growth and Tech-pushed European businesses
-
Global buyers will be equipped to observe the Euronext Tech Leaders phase by way of a new index
Daix (France), Prolonged Island City (New York, United States), June 7, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Business”), a clinical-stage biopharmaceutical business concentrated on the development of oral modest molecule therapies for the remedy of people with non-alcoholic steatohepatitis (NASH) and other conditions with major unmet healthcare requirements, today introduced that it will join the Euronext Tech Leaders initiative, a new Euronext phase comprised of far more than 100 large-expansion and main Tech providers across Europe.
Frédéric Cren, Chairman, Chief Government Officer and cofounder of Inventiva, mentioned: “We are proud to sign up for other Tech Leaders in this new phase. This is a recognition of our successes and our international likely as a tech-driven biopharmaceutical firm, and we are self-assured that getting section of this worldwide initiative will bring even more exposure to Inventiva. This is a terrific tribute to the do the job and devotion of all Inventiva staff.”
To be provided, corporations need to fulfill a distinct set of fiscal standards, together with a market capitalization of € 300 million and bare minimum growth charge conditions. This phase aims to be a catalyst for the next technology of Tech Leaders, which stand to advantage from Euronext’s sturdy visibility and international investor foundation. Investors will be equipped to monitor Euronext Tech Leaders with a new, dedicated index that turns into accessible in July.
About Euronext
Euronext is the foremost pan-European market place infrastructure, connecting European economies to global funds markets, to accelerate innovation and sustainable advancement. It operates regulated exchanges in Belgium, France, Ireland, Italy, the Netherlands, Norway and Portugal. With near to 2,000 detailed issuers and all over €6.6 trillion in current market capitalisation as of conclusion March 2022, it has an unmatched blue-chip franchise and a sturdy varied domestic and global customer foundation. Euronext operates regulated and clear fairness and derivatives markets, one particular of Europe’s leading digital fixed cash flow buying and selling marketplaces and is the largest centre for debt and resources listings in the world. Its complete products featuring incorporates Equities, Fx, Trade Traded Resources, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. The Group supplies a multi-asset clearing household by means of Euronext Clearing, and custody and settlement products and services as a result of Euronext Securities central securities depositories in Denmark, Italy, Norway and Portugal. Euronext also leverages its skills in operating markets by giving technological innovation and managed solutions to 3rd parties. In addition to its primary regulated sector, it also operates a variety of junior marketplaces, simplifying entry to listing for SMEs. For the most recent information, go to euronext.com or follow us on Twitter (twitter.com/euronext) and LinkedIn (linkedin.com/euronext).
About Inventiva
Inventiva is a clinical-stage biopharmaceutical business centered on the investigate and growth of oral compact molecule therapies for the cure of people with NASH and other health conditions with substantial unmet health care wants. The Corporation advantages from a sturdy know-how and practical experience in the area of compounds focusing on nuclear receptors, transcription aspects and epigenetic modulation. Inventiva’s direct product or service candidate, lanifibranor, is at this time in a pivotal Stage III clinical trial, NATiV3, for the remedy of adult clients with NASH, a prevalent and progressive continual liver condition for which there are at the moment no accredited therapies.
The Enterprise has recognized a strategic collaboration with AbbVie in the place of autoimmune illnesses that resulted in the discovery of the drug applicant cedirogant (ABBV-157), an oral RORg inverse agonist which is currently being evaluated in a Section IIb medical demo, led by AbbVie, in grownup patients with moderate to extreme continual plaque psoriasis. Inventiva’s pipeline also incorporates odiparcil, a drug candidate for the remedy of adult mucopolysaccharidoses (MPS) VI sufferers. As component of Inventiva’s decision to concentration medical attempts on the enhancement of lanifibranor, it suspended its scientific endeavours relating to odiparcil and is examining accessible alternatives with regard to its prospective additional growth. Inventiva is in the process of deciding upon an oncology progress candidate for its Hippo signalling pathway method.
The Firm has a scientific crew of around 80 people today with deep experience in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, and clinical growth. It owns an intensive library of about 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as nicely as a wholly‑owned study and growth facility.
Inventiva is a general public business mentioned on compartment C of the regulated market of Euronext Paris (ticker: IVA – ISIN: FR0013233012) and on the Nasdaq International Market in the United States (ticker: IVA). www.inventivapharma.com.
Contacts
Crucial Observe
This press release includes “forward-seeking statements” within the that means of the harmless harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historic facts, involved in this press launch are ahead-on the lookout statements. These statements incorporate, but are not constrained to, forecasts and estimates with respect to Inventiva’s pre-clinical plans and medical trials, clinical demo knowledge releases, together with for element 1 of the Phase III medical demo of lanifibranor in clients with NASH, pipeline and preclinical and medical advancement programs, reaching expected milestones and situations precedent for Tranche A and/or Tranche B, probable upcoming financings and strategic transactions, milestone payments, royalties and item revenue, potential routines, expectations, designs, growth and potential clients of Inventiva and the sufficiency of Inventiva’s income methods and cash runway. Selected of these statements, forecasts and estimates can be recognized by the use of phrases these as, without the need of limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will”, “would”, “could”, “might”, “should”, and “continue” and similar expressions. This sort of statements are not historical points but fairly are statements of long term expectations and other forward-seeking statements that are primarily based on management’s beliefs. These statements replicate this sort of views and assumptions prevailing as of the day of the statements and involve regarded and not known hazards and uncertainties that could bring about potential benefits, functionality or upcoming activities to vary materially from people expressed or implied in this sort of statements. Long run functions are hard to predict and might rely on variables that are past Inventiva’s regulate. There can be no guarantees with respect to pipeline solution candidates that the clinical trial success will be obtainable on their expected timeline, that long term medical trials will be initiated as predicted, that solution candidates will acquire the necessary regulatory approvals, or that any of the anticipated milestones by Inventiva or its partners will be achieved or that conditions precedent to obtain funds underneath the credit history facility will be met on their expected timeline, or at all. Actual success may flip out to be materially distinct from the anticipated potential success, efficiency or achievements expressed or implied by these statements, forecasts and estimates, because of to a range of variables, which includes that Inventiva is a scientific-stage firm with no accepted products and solutions and no historic products revenues, Inventiva has incurred significant losses given that inception, Inventiva has a confined functioning history and has by no means generated any income from products revenue, Inventiva will have to have more money to finance its operations, Inventiva’s long run achievements is dependent on the thriving medical growth, regulatory approval and subsequent commercialization of present and any long run product or service candidates, preclinical reports or before clinical trials are not necessarily predictive of foreseeable future effects and the outcomes of Inventiva’s clinical trials might not assist Inventiva’s product candidate claims, Inventiva could face considerable delays in its clinical trials or Inventiva may possibly are unsuccessful to show security and efficacy to the satisfaction of applicable regulatory authorities, enrolment and retention of sufferers in clinical trials is an high-priced and time-consuming course of action and could be produced extra hard or rendered impossible by a number of factors outside Inventiva’s regulate, Inventiva’s merchandise candidates may possibly lead to adverse drug reactions or have other houses that could delay or avoid their regulatory approval, or restrict their industrial opportunity, Inventiva faces considerable level of competition and Inventiva’s business, and preclinical studies and scientific development packages and timelines, its economic situation and success of functions could be materially and adversely afflicted by the present-day COVID-19 pandemic and geopolitical situations, this sort of as the conflict involving Russia and Ukraine, which could hold off the initiation, enrolment and completion of Inventiva’s scientific trials on expected timelines or at all. Supplied these hazards and uncertainties, no representations are built as to the precision or fairness of these types of ahead-on the lookout statements, forecasts and estimates. Moreover, ahead-searching statements, forecasts and estimates only communicate as of the date of this push launch. Audience are cautioned not to spot undue reliance on any of these ahead-searching statements.
You should refer to the Common Registration Doc for the year finished December 31, 2021 filed with the Autorité des Marchés Financiers on March 11, 2022 and the Yearly Report on Variety 20-F for the 12 months ended December 31, 2021 filed with the Securities and Exchange Commission on March 11, 2022 for added information and facts in relation to such aspects, risks and uncertainties.
All details in this press release is as of the date of the launch. Other than as necessary by law, Inventiva has no intention and is underneath no obligation to update or review the forward-hunting statements referred to previously mentioned.
Attachment
